Activation of sphingosine kinase-1 in cancer: Implications for therapeutic targeting

Current Molecular Pharmacology

Volumn 3, Issue 2, 2010, Pages 53-65

  Cuvillier, Olivier ^a,b,c   Ader, Isabelle ^a,b   Bouquerel, Pierre ^a,b   Brizuela, Leyre ^a,b   Malavaud, Bernard ^a,b,c   Mazerolles, Catherine ^a,b,c   Rischmann, Pascal ^a,b,c  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU RANGUEIL   (France)

Author keywords

Antagonists Inhibitors; Ceramide; Sphingolipids; Sphingosine; Sphingosine 1 phosphate; Sphingosine kinase 1; Therapeutic antibody

Indexed keywords

ANTINEOPLASTIC AGENT; B 5354 C; CAMPTOTHECIN; CERAMIDE; CYTARABINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; F 12509 A; IMATINIB; MANUMYCIN; SKI 1; SKI 2; SKI 5; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASTROCYTOMA; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL PROTECTION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DOWN REGULATION; DRUG INACTIVATION; DRUG POTENCY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER;

APOPTOSIS; CERAMIDES; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE;

EID: 77953671696     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211003020053     Document Type: Article

References (115)

1. Spiegel, S.; Milstien, S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell. Biol., 2003, 4, 397-407.
2. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P.G.; Coso, O.A.; Gutkind, S.; Spiegel, S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 1996, 381, 800-803.
3. Kohama, T.; Olivera, A.; Edsall, L.; Nagiec, M.M.; Dickson, R.; Spiegel, S. Molecular cloning and functional characterization of murine sphingosine kinase. J. Biol. Chem., 1998, 273, 23722-23728.
4. Xia, P.; Gamble, J. R.; Wang, L.; Pitson, S. M.; Moretti, P. A.; Wattenberg, B. W.; D'Andrea, R. J.; Vadas, M. A. An oncogenic role of sphingosine kinase. Curr. Biol., 2000, 10, 1527-1530.
5. Alvarez, S.E.; Milstien, S.; Spiegel, S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol. Metab., 2007, 18, 300-307.
6. Johnson, K.R.; Becker, K.P.; Facchinetti, M.M.; Hannun, Y.A.; Obeid, L.M. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J. Biol. Chem., 2002, 277, 35257-35262.
7. Pitson, S.M.; Xia, P.; Leclercq, T.M.; Moretti, P.A.; Zebol, J.R.; Lynn, H.E.; Wattenberg, B.W.; Vadas, M.A. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med., 2005, 201, 49-54.
8. Jarman, K.E.; Moretti, P.A.; Zebol, J.R.; Pitson, S.M. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. J. Biol. Chem., 2010, 285, 483-492.
9. Liu, H.; Toman, R.E.; Goparaju, S.K.; Maceyka, M.; Nava, V.E.; Sankala, H.; Payne, S.G.; Bektas, M.; Ishii, I.; Chun, J.; Milstien, S.; Spiegel, S. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem., 2003, 278, 40330-40336.
10. Maceyka, M.; Sankala, H.; Hait, N.C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.S.; Merrill, A.H., Jr.; Milstien, S.; Spiegel, S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 2005, 280, 37118-37129.
11. French, K.J.; Schrecengost, R.S.; Lee, B.D.; Zhuang, Y.; Smith, S.N.; Eberly, J.L.; Yun, J.K.; Smith, C.D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63, 5962-5969.
12. Johnson, K.R.; Johnson, K.Y.; Crellin, H.G.; Ogretmen, B.; Boylan, A.M.; Harley, R.A.; Obeid, L.M. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J. Histochem. Cytochem., 2005, 53, 1159-1166.
13. Bayerl, M.G.; Bruggeman, R.D.; Conroy, E.J.; Hengst, J.A.; King, T.S.; Jimenez, M.; Claxton, D.F.; Yun, J.K. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk. Lymphoma., 2008, 49, 948-954.
14. Sobue, S.; Iwasaki, T.; Sugisaki, C.; Nagata, K.; Kikuchi, R.; Murakami, M.; Takagi, A.; Kojima, T.; Banno, Y.; Akao, Y.; Nozawa, Y.; Kannagi, R.; Suzuki, M.; Abe, A.; Naoe, T.; Murate, T. Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leukemia, 2006, 20, 2042-2046.
15. Van Brocklyn, J.R.; Jackson, C.A.; Pearl, D.K.; Kotur, M.S.; Snyder, P.J.; Prior, T.W. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J. Neuropathol. Exp. Neurol., 2005, 64, 695-705.
16. Li, J.; Guan, H.Y.; Gong, L.Y.; Song, L.B.; Zhang, N.; Wu, J.; Yuan, J.; Zheng, Y.J.; Huang, Z.S.; Li, M. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin. Cancer Res., 2008, 14, 6996-7003.
17. Ruckhaberle, E.; Rody, A.; Engels, K.; Gaetje, R.; von Minckwitz, G.; Schiffmann, S.; Grosch, S.; Geisslinger, G.; Holtrich, U.; Karn, T.; Kaufmann, M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat., 2008, 112, 41-52.
18. Li, W.; Yu, C.P.; Xia, J.T.; Zhang, L.; Weng, G.X.; Zheng, H.Q.; Kong, Q.L.; Hu, L.J.; Zeng, M.S.; Zeng, Y.X.; Li, M.; Li, J.; Song, L.B. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res., 2009, 15, 1393-1399.
19. Kawamori, T.; Kaneshiro, T.; Okumura, M.; Maalouf, S.; Uflacker, A.; Bielawski, J.; Hannun, Y.A.; Obeid, L.M. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB. J., 2009, 23, 405-414.
20. Kawamori, T.; Osta, W.; Johnson, K.R.; Pettus, B.J.; Bielawski, J.; Tanaka, T.; Wargovich, M.J.; Reddy, B.S.; Hannun, Y.A.; Obeid, L.M.; Zhou, D. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB. J., 2006, 20, 386-388.
21. Kohno, M.; Momoi, M.; Oo, M.L.; Paik, J.H.; Lee, Y.M.; Venkataraman, K.; Ai, Y.; Ristimaki, A.P.; Fyrst, H.; Sano, H.; Rosenberg, D.; Saba, J.D.; Proia, R.L.; Hla, T. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol. Cell. Biol., 2006, 26, 7211-7223.
22. Guillermet-Guibert, J.; Davenne, L.; Pchejetski, D.; Saint-Laurent, N.; Brizuela, L.; Guilbeau-Frugier, C.; Delisle, M.B.; Cuvillier, O.; Susini, C.; Bousquet, C. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol. Cancer Ther., 2009, 8, 809-820.
23. Dayon, A.; Brizuela, L;, Martin, C.; Mazerolles, C.; Pirot, N.; Doumerc, N.; Nogueira, L.; Golzio, M.; Teissié, J.; Serre, G.; Rischmann, P.; Malavaud, B.; Cuvillier, O. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One, 2009, 4, e8048.
24. Sutphen, R.; Xu, Y.; Wilbanks, G.D.; Fiorica, J.; Grendys, E.C., Jr.; LaPolla, J.P.; Arango, H.; Hoffman, M.S.; Martino, M.; Wakeley, K.; Griffin, D.; Blanco, R.W.; Cantor, A.B.; Xiao, Y.J.; Krischer, J.P. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2004, 13, 1185-1191.
25. Senchenkov, A.; Litvak, D.A.; Cabot, M.C. Targeting ceramide metabolism--a strategy for overcoming drug resistance. J. Natl. Cancer Inst., 2001, 93, 347-357.
26. Ogretmen, B.; Hannun, Y.A. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resistance Updates, 2001, 4, 368-377.
27. Chmura, S.J.; Nodzenski, E.; Beckett, M.A.; Kufe, D.W.; Quintans, J.; Weichselbaum, R.R. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res., 1997, 57, 1270-1275.
28. Michael, J.M.; Lavin, M.F.; Watters, D.J. Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Cancer Res., 1997, 57, 3600-3605.
29. Bruno, A.P.; Laurent, G.; Averbeck, D.; Demur, C.; Bonnet, J.; Bettaieb, A.; Levade, T.; Jaffrezou, J.P. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell. Death Differ., 1998, 5, 172-182.
30. Nava, V.E.; Cuvillier, O.; Edsall, L.C.; Kimura, K.; Milstien, S.; Gelmann, E.P.; Spiegel, S. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res., 2000, 60, 4468-4474.
31. Itoh, M.; Kitano, T.; Watanabe, M.; Kondo, T.; Yabu, T.; Taguchi, Y.; Iwai, K.; Tashima, M.; Uchiyama, T.; Okazaki, T. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin. Cancer Res., 2003, 9, 415-423.
32. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006, 20, 95-102.
33. Taha, T.A.; Osta, W.; Kozhaya, L.; Bielawski, J.; Johnson, K.R.; Gillanders, W.E.; Dbaibo, G.S.; Hannun, Y.A.; Obeid, L.M. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J. Biol. Chem., 2004, 279, 20546-20554.
34. Baran, Y.; Salas, A.; Senkal, C.E.; Gunduz, U.; Bielawski, J.; Obeid, L.M.; Ogretmen, B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282, 10922-10934.
35. Li, Q.F.; Huang, W.R.; Duan, H.F.; Wang, H.; Wu, C.T.; Wang, L.S. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene, 2007, 26, 7904-7908.
36. Bonhoure, E.; Lauret, A.; Barnes, D.J.; Martin, C.; Malavaud, B.; Kohama, T.; Melo, J.V.; Cuvillier, O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia, 2008, 22, 971-979.
37. Sobue, S.; Nemoto, S.; Murakami, M.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Nakamura, M.; Ito, Y.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int. J. Hematol., 2008, 87, 266-275.
38. Pchejetski, D.; Golzio, M.; Bonhoure, E.; Calvet, C.; Doumerc, N.; Garcia, V.; Mazerolles, C.; Rischmann, P.; Teissie, J.; Malavaud, B.; Cuvillier, O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res., 2005, 65, 11667-11675.
39. Pchejetski, D.; Doumerc, N.; Golzio, M.; Naymark, M.; Teissie, J.; Kohama, T.; Waxman, J.; Malavaud, B.; Cuvillier, O. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol. Cancer Ther. 2008, 7, 1836-1845.
40. Abe, A.; Shayman, J.A.; Radin, N.S. A novel enzyme that catalyzes the esterification of N-acetylsphingosine. J. Biol. Chem., 1996, 271, 14383-14389.
41. Nava, V.E.; Hobson, J.P.; Murthy, S.; Milstien, S.; Spiegel, S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell. Res., 2002, 281, 115-127.
42. Olivera, A.; Kohama, T.; Edsall, L.; Nava, V.; Cuvillier, O.; Poulton, S.; Spiegel, S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell. Biol., 1999, 147, 545-558.
43. Edsall, L.C.; Cuvillier, O.; Twitty, S.; Spiegel, S.; Milstien, S. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J. Neurochem., 2001, 76, 1573-1584.
44. Pchejetski, D.; Kunduzova, O.; Dayon, A.; Calise, D.; Seguelas, M.H.; Leducq, N.; Seif, I.; Parini, A.; Cuvillier, O. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ. Res., 2007, 100, 41-49.
45. Bektas, M.; Jolly, P.S.; Muller, C.; Eberle, J.; Spiegel, S.; Geilen, C.C. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene, 2005, 24, 178-187.
46. Gomez-Brouchet, A.; Pchejetski, D.; Brizuela, L.; Garcia, V.; Altie, M.F.; Maddelein, M.L.; Delisle, M.B.; Cuvillier, O. Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol. Pharmacol., 2007, 72, 341-349.
47. Sauer, L.; Nunes, J.; Salunkhe, V.; Skalska, L.; Kohama, T.; Cuvillier, O.; Waxman, J.; Pchejetski, D. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int. J. Cancer, 2009, 125, 2728-2736.
48. Cuvillier, O.; Rosenthal, D.S.; Smulson, M.E.; Spiegel, S. Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. J. Biol. Chem., 1998, 273, 2910-2916.
49. Cuvillier, O.; Levade, T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood, 2001, 98, 2828-2836.
50. Betito, S.; Cuvillier, O. Regulation by sphingosine 1-phosphate of Bax and Bad activities during apoptosis in a MEK-dependent manner. Biochem. Biophys. Res. Commun., 2006, 340, 1273-1277.
51. Jain, R.K. Taming vessels to treat cancer. Sci. Am. 2008, 298, 56-63.
52. Semenza, G.L. Hypoxia and cancer. Cancer Metastasis Rev., 2007, 26, 223-224.
53. Wang, G.L.; Semenza, G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem., 1995, 270, 1230-1237.
54. Fong, G.H. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis, 2008, 11, 121-140.
55. Jin, Z.Q.; Zhang, J.; Huang, Y.; Hoover, H.E.; Vessey, D.A.; Karliner, J.S. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc. Res., 2007, 76, 41-50.
56. Yun, J.K.; Kester, M. Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. Arch. Biochem. Biophys., 2002, 408, 78-86.
57. Ahmad, M.; Long, J.S.; Pyne, N.J.; Pyne, S. The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins Other Lipid Mediat., 2006, 79, 278-286.
58. Tao, R.; Zhang, J.; Vessey, D.A.; Honbo, N.; Karliner, J.S. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc. Res., 2007, 74, 56-63.
59. Anelli, V.; Gault, C.R.; Cheng, A.B.; Obeid, L.M. Sphingosine Kinase 1 Is Up-regulated during Hypoxia in U87MG Glioma Cells. J. Biol. Chem., 2008, 283, 3365-3375.
60. Schwalm, S.; Doll, F.; Romer, I.; Bubnova, S.; Pfeilschifter, J.; Huwiler, A. Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochem. Biophys. Res. Commun., 2008, 368, 1020-1025.
61. Ader, I.; Brizuela, L.; Bouquerel, P.; Malavaud, B.; Cuvillier, O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res., 2008, 68, 8635-8642.
62. Ader, I.; Malavaud, B.; Cuvillier, O. When the sphingosine kinase-1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res., 2009, 69, 3723-3726.
63. Cuvillier, O. Sphingosine kinase-1--a potential therapeutic target in cancer. Anticancer Drugs, 2007, 18, 105-110.
64. Taha, T.A.; Kitatani, K.; El-Alwani, M.; Bielawski, J.; Hannun, Y.A.; Obeid, L.M. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J., 2006, 20, 482-484.
65. Kapitonov, D.; Allegood, J.C.; Mitchell, C.; Hait, N.C.; Almenara, J.A.; Adams, J.K.; Zipkin, R.E.; Dent, P.; Kordula, T.; Milstien, S.; Spiegel, S. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res., 2009, 69, 6915-6923.
66. Cuvillier, O.; Edsall, L.; Spiegel, S. Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells. J. Biol. Chem., 2000, 275, 15691-15700.
67. Cuvillier, O.; Nava, V.E.; Murthy, S.K.; Edsall, L.C.; Levade, T.; Milstien, S.; Spiegel, S. Sphingosine generation, cytochrome c release, and activation of caspase-7 in doxorubicin-induced apoptosis of MCF7 breast adenocarcinoma cells. Cell. Death Differ, 2001, 8, 162-171.
68. Olivera, A.; Kohama, T.; Tu, Z.; Milstien, S.; Spiegel, S. Purification and characterization of rat kidney sphingosine kinase. J. Biol. Chem., 1998, 273, 12576-12583.
69. Vessey, D.A.; Kelley, M.; Zhang, J.; Li, L.; Tao, R.; Karliner, J.S. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J. Biochem. Mol. Toxicol., 2007, 21, 273-279.
70. Cuvillier, O.; Levade, T. Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacol. Res., 2003, 47, 439-445.
71. Igarashi, Y.; Hakomori, S.; Toyokuni, T.; Dean, B.; Fujita, S.; Sugimoto, M.; Ogawa, T.; el-Ghendy, K.; Racker, E. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry, 1989, 28, 6796-6800.
72. Khan, W.A.; Dobrowsky, R.; el Touny, S.; Hannun, Y.A. Protein kinase C and platelet inhibition by D-erythro-sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem. Biophys. Res. Commun., 1990, 172, 683-691.
73. Jarvis, W.D.; Fornari, F.A., Jr.; Tombes, R.M.; Erukulla, R.K.; Bittman, R.; Schwartz, G.K.; Dent, P.; Grant, S. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol. Pharmacol., 1998, 54, 844-856.
74. Kim, J.W.; Kim, Y.W.; Inagaki, Y.; Hwang, Y.A.; Mitsutake, S.; Ryu, Y.W.; Lee, W.K.; Ha, H.J.; Park, C.S.; Igarashi, Y. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg. Med. Chem., 2005, 13, 3475-3485.
75. Cuvillier, O. Sphingosine in apoptosis signaling. Biochim. Biophys. Acta, 2002, 1585, 153-162.
76. Woodcock, J. Sphingosine and ceramide signalling in apoptosis. IUBMB Life, 2006, 58, 462-466.
77. French, K.J.; Upson, J.J.; Keller, S.N.; Zhuang, Y.; Yun, J.K.; Smith, C.D. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther., 2006, 318, 596-603.
78. Xiang, Y.; Asmussen, G.; Booker, M.; Hirth, B.; Kane, J. L., Jr.; Liao, J.; Noson, K.D.; Yee, C. Discovery of novel sphingosine kinase 1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 6119-6121.
79. Kono, K.; Tanaka, M.; Mizuno, T.; Kodama, K.; Ogita, T.; Kohama, T. B-5354a, b and c, new sphingosine kinase inhibitors, produced by a marine bacterium; taxonomy, fermentation, isolation, physico-chemical properties and structure determination. J. Antibiot. (Tokyo), 2000, 53, 753-758.
80. Kono, K.; Tanaka, M.; Ogita, T.; Hosoya, T.; Kohama, T. F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J. Antibiot. (Tokyo), 2000, 53, 459-466.
81. Kono, K.; Tanaka, M.; Ogita, T.; Kohama, T. Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J. Antibiot. (Tokyo), 2000, 53, 759-764.
82. Kono, K.; Tanaka, M.; Ono, Y.; Hosoya, T.; Ogita, T.; Kohama, T. S-15183a and b, new sphingosine kinase inhibitors, produced by a fungus. J. Antibiot. (Tokyo), 2001, 54, 415-420.
83. Kono, K.; Sugiura, M.; Kohama, T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J. Antibiot. (Tokyo), 2002, 55, 99-103.
84. Akao, Y.; Banno, Y.; Nakagawa, Y.; Hasegawa, N.; Kim, T.J.; Murate, T.; Igarashi, Y.; Nozawa, Y. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem. Biophys. Res. Commun., 2006, 342, 1284-1290.
85. Paugh, S.W.; Paugh, B.S.; Rahmani, M.; Kapitonov, D.; Almenara, J.A.; Kordula, T.; Milstien, S.; Adams, J.K.; Zipkin, R.E.; Grant, S.; Spiegel, S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood, 2008, 112, 1382-1391.
86. Albert, R.; Hinterding, K.; Brinkmann, V.; Guerini, D.; Muller-Hartwieg, C.; Knecht, H.; Simeon, C.; Streiff, M.; Wagner, T.; Welzenbach, K.; Zecri, F.; Zollinger, M.; Cooke, N.; Francotte, E. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J. Med. Chem., 2005, 48, 5373-5377.
87. Kiuchi, M.; Adachi, K.; Tomatsu, A.; Chino, M.; Takeda, S.; Tanaka, Y.; Maeda, Y.; Sato, N.; Mitsutomi, N.; Sugahara, K.; Chiba, K. Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. Bioorg. Med. Chem., 2005, 13, 425-432.
88. Paugh, S.W.; Payne, S.G.; Barbour, S.E.; Milstien, S.; Spiegel, S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett., 2003, 554, 189-193.
89. Kharel, Y.; Lee, S.; Snyder, A.H.; Sheasley-O'neill, S.L.; Morris, M.A.; Setiady, Y.; Zhu, R.; Zigler, M.A.; Burcin, T.L.; Ley, K.; Tung, K.S.; Engelhard, V.H.; Macdonald, T.L.; Pearson-White, S.; Lynch, K.R. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem., 2005, 280, 36865-36872.
90. Brinkmann, V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther., 2007, 115, 84-105.
91. Neviani, P.; Santhanam, R.; Oaks, J.J.; Eiring, A.M.; Notari, M.; Blaser, B.W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B.J.; Cortes, J.; Marcucci, G.; Chen, C.S.; Verrills, N.M.; Roy, D.C.; Caligiuri, M.A.; Bloomfield, C.D.; Byrd, J.C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117, 2408-2421.
92. Wang, J.D.; Takahara, S.; Nonomura, N.; Ichimaru, N.; Toki, K.; Azuma, H.; Matsumiya, K.; Okuyama, A.; Suzuki, S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate, 1999, 40, 50-55.
93. Permpongkosol, S.; Wang, J.D.; Takahara, S.; Matsumiya, K.; Nonomura, N.; Nishimura, K.; Tsujimura, A.; Kongkanand, A.; Okuyama, A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int. J. Cancer, 2002, 98, 167-172.
94. Chua, C.W.; Lee, D.T.; Ling, M.T.; Zhou, C.; Man, K.; Ho, J.; Chan, F.L.; Wang, X.; Wong, Y.C. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer, 2005, 117, 1039-1048.
95. Sonoda, Y.; Yamamoto, D.; Sakurai, S.; Hasegawa, M.; Aizu-Yokota, E.; Momoi, T.; Kasahara, T. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun., 2001, 281, 282-288.
96. Azuma, H.; Takahara, S.; Ichimaru, N.; Wang, J.D.; Itoh, Y.; Otsuki, Y.; Morimoto, J.; Fukui, R.; Hoshiga, M.; Ishihara, T.; Nonomura, N.; Suzuki, S.; Okuyama, A.; Katsuoka, Y. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res., 2002, 62, 1410-1419.
97. Azuma, H.; Horie, S.; Muto, S.; Otsuki, Y.; Matsumoto, K.; Morimoto, J.; Gotoh, R.; Okuyama, A.; Suzuki, S.; Katsuoka, Y.; Takahara, S. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res., 2003, 23, 3183-3193.
98. Nagahara, Y.; Matsuoka, Y.; Saito, K.; Ikekita, M.; Higuchi, S.; Shinomiya, T. Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn. J. Cancer Res., 2001, 92, 680-687.
99. Matsuoka, Y.; Nagahara, Y.; Ikekita, M.; Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol., 2003, 138, 1303-1312.
100. Liu, Q.; Zhao, X.; Frissora, F.; Ma, Y.; Santhanam, R.; Jarjoura, D.; Lehman, A.; Perrotti, D.; Chen, C.S.; Dalton, J.T.; Muthusamy, N.; Byrd, J.C. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 2008, 111, 275-284.
101. Azuma, H.; Takahara, S.; Horie, S.; Muto, S.; Otsuki, Y.; Katsuoka, Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol., 2003, 169, 2372-2377.
102. Lee, T.K.; Man, K.; Ho, J.W.; Sun, C.K.; Ng, K.T.; Wang, X.H.; Wong, Y.C.; Ng, I.O.; Xu, R.; Fan, S.T. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis, 2004, 25, 2397-2405.
103. Lee, T.K.; Man, K.; Ho, J.W.; Wang, X.H.; Poon, R.T.; Xu, Y.; Ng, K.T.; Chu, A.C.; Sun, C.K.; Ng, I.O.; Sun, H.C.; Tang, Z.Y.; Xu, R.; Fan, S.T. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res., 2005, 11, 8458-8466.
104. Ng, K.T.; Man, K.; Ho, J.W.; Sun, C.K.; Lee, T.K.; Zhao, Y.; Lo, C.M.; Poon, R.T.; Fan, S.T. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. Int. J. Oncol., 2007, 30, 375-380.
105. Ubai, T.; Azuma, H.; Kotake, Y.; Inamoto, T.; Takahara, K.; Ito, Y.; Kiyama, S.; Sakamoto, T.; Horie, S.; Muto, S.; Takahara, S.; Otsuki, Y.; Katsuoka, Y. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res., 2007, 27, 75-88.
106. Shen, Y.; Cai, M.; Xia, W.; Liu, J.; Zhang, Q.; Xie, H.; Wang, C.; Wang, X.; Zheng, S. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett., 2007, 254, 288-297.
107. Barr, R.K.; Lynn, H.E.; Moretti, P.A.; Khew-Goodall, Y.; Pitson, S.M. Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J. Biol. Chem., 2008, 283, 34994-35002.
108. Payne, S.G.; Oskeritzian, C.A.; Griffiths, R.; Subramanian, P.; Barbour, S.E.; Chalfant, C.E.; Milstien, S.; Spiegel, S. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 2007, 109, 1077-1085.
109. Paugh, S.W.; Cassidy, M.P.; He, H.; Milstien, S.; Sim-Selley, L.J.; Spiegel, S.; Selley, D.E. Sphingosine and its analog, the immuno-suppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol. Pharmacol., 2006, 70, 41-50.
110. LaMontagne, K.; Littlewood-Evans, A.; Schnell, C.; O'Reilly, T.; Wyder, L.; Sanchez, T.; Probst, B.; Butler, J.; Wood, A.; Liau, G.; Billy, E.; Theuer, A.; Hla, T.; Wood, J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res., 2006, 66, 221-231.
111. Liu, Y.; Wada, R.; Yamashita, T.; Mi, Y.; Deng, C.X.; Hobson, J.P.; Rosenfeldt, H.M.; Nava, V.E.; Chae, S.S.; Lee, M.J.; Liu, C.H.; Hla, T.; Spiegel, S.; Proia, R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest., 2000, 106, 951-961.
112. Visentin, B.; Vekich, J.A.; Sibbald, B.J.; Cavalli, A.L.; Moreno, K.M.; Matteo, R.G.; Garland, W.A.; Lu, Y.; Yu, S.; Hall, H.S.; Kundra, V.; Mills, G.B.; Sabbadini, R.A. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 2006, 9, 225-238.
113. O'Brien, N.; Jones, S.T.; Williams, D.G.; Cunningham, H.B.; Moreno, K.; Visentin, B.; Gentile, A.; Vekich, J.; Shestowsky, W.; Hiraiwa, M.; Matteo, R.; Cavalli, A.; Grotjahn, D.; Grant, M.; Hansen, G.; Campbell, M. A.; Sabbadini, R. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J. Lipid Res., 2009, 50, 2245-2257.
114. Wojciak, J.M.; Zhu, N.; Schuerenberg, K.T.; Moreno, K.; Shestowsky, W.S.; Hiraiwa, M.; Sabbadini, R.; Huxford, T. The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen. Proc. Natl. Acad. Sci. USA, 2009, 106, 17717-17722.
115. Sabbadini, R.A. Targeting sphingosine-1-phosphate for cancer therapy. Br. J. Cancer, 2006, 95, 1131-1135.